The link didn't work...
is this the story?
Technology transfer company of the Hebrew University of Jerusalem, Yissum, licensed molecule called N-acetylcysteine amide (AD4) to Eucalyptus Ltd.
The molecule is an antioxidant for the prevention and treatment of Parkinson’s, Alzheimer’s, multiple sclerosis and other neurodegenerative diseases that are linked to oxidative stress, and also has broader applications in biology. As per the agreement, the orally–available AD4 will be used for such purposes as the treatment of neurodegenerative diseases, among others.
The announcement reveals that Eucalyptus has worldwide exclusive rights to develop and commercialize the molecule. Yissum, Ramot and Mor Research Applications, will receive upfront and milestone payments based on development progress and royalties from sales of final products.
Professor Ashley Bush, CSO, Eucalyptus, commented: “I am very confident that AD4 will be therapeutically useful for several major neurological disorders, certain major psychiatric conditions as well as several other biological applications. I expect this to be a rapid development project.